الفهرس Only 14 pages are availabe for public view
 |  | from | 200 |  |  |
| | | from | 200 | | |
Abstract
Hepatic tumors are tumors or growth on or in the liver. These growths can be benign or malignant. They may be discovered on medical imaging or may be present in patient as abdominal mass, hepatomegaly, jaundice, abdominal pain or some other dysfunction (Maygonkal, 2006).
Tumors of liver may be benign or malignant. The latter may be primary or secondary. The liver as a site for metastasis may be related to the fact that it is largest organ in the body and it filters blood from both the systemic and portal circulations (Choiby et al., 2005).
Despite advances in cancer therapy the treatment of liver
Tumors remain a challenge. Most patients are poor candidates for surgical resection (Lai el al., 2007)
Surgical resection is not always possible since it depend on different factors (Jadehomsi et al., 2006).
The resectability rate of hepatocelleular carcinoma However has remained rather low mainly because of the underlying liver cirrhosis (Habib et al., 1993).
Patients with metastatic disease are usually not eligible for hepatic resection due to either the frequent multiplicity of lesions or the relative degree of difficulty of the operation.
Furthermore recurrent metastatic diseases in post surgical residual liver is not uncommon and only minorities of such patients are candidates for repeated resection (Lai el al., 1995).
Liver transplantation may simultaneously cure the tumor and underling cirrhosis but the major drawback of transplantation is the rarity of donors. The enlargement of waiting time has led to 20% of the candidates to DROP out before receiving the procedure (Lopez et al., 2006).
Minimal invasive technique used recently for treatment of non respectable liver tumors. These include (micro-waves, laser, radiofrequency, cryo-ablation, ethanol injection, and chemo-embolization).
Nowadays there are RCT (Randomized controller trials) testing for Tyrosine kinas inhibitor, anti-angiogenic agents in hepatocellular carcinoma patients. Another trials during the last years for using gene therapy in hepatocelleular carcinoma patients with advanced tumors (Lopez et al., 2006).